Ascending as a new biopharmaceutical force

Vision 3×3

A Strategic Roadmap for Sustainable Growth

At Ascendis, we are working to build a leading, fully integrated biopharma company that provides meaningful improvement in patients’ lives. With the successful accomplishments of Vision 20/20, we have implemented a new strategic roadmap through 2025, Vision 3×3. The goal of Vision 3×3 is to achieve sustainable growth through multiple approaches:

  • Obtain regulatory approval for three endocrinology rare disease products:
    • TransCon hGH for pediatric growth hormone deficiency
    • TransCon PTH for adult hypoparathyroidism
    • TransCon CNP for achondroplasia
  • Create further growth of our endocrinology rare disease pipeline through:
    • Label expansion programs, with the goal of obtaining 9 indications in total
    • Global clinical reach, either directly or through partnerships
  • Build an integrated commercial business for the endocrinology rare disease franchise in North America and select European countries, and establish a global commercial presence with partners in other geographic areas
  • Create three independent therapeutic areas, each with a diversified pipeline built on TransCon technologies and our unique algorithm for product innovation. We have established oncology as the next independent therapeutic area

Introduced in January 2019, Vision 3×3 speaks to where we are today, with 3 potentially best-in-class endocrinology rare disease product candidates in clinical development. It also speaks to our aspirations—how we intend to multiply our success to address unmet patient needs.

You are about to access www.ascendispharma.us. The information on this website is intended for residents of the United States. Click below to confirm you are a citizen and/or resident of the United States.

Go

You are about to access www.ascendispharma.us. The information on this website is intended for residents of the United States. Click below to confirm you are a citizen and/or resident of the United States.

Go